Literature DB >> 8441240

The spectrum of bone disease in end-stage renal failure--an evolving disorder.

D J Sherrard1, G Hercz, Y Pei, N A Maloney, C Greenwood, A Manuel, C Saiphoo, S S Fenton, G V Segre.   

Abstract

We have assessed the bone histology in 259 chronic dialysis patients, all of whom were in the same dialysis program. All patients had bone biopsies with quantitative histomorphometry, intact parathyroid hormone (PTH) measurements, basal and deferoxamine stimulated serum aluminum levels. Results demonstrate the increased incidence of the recently described aplastic bone lesion, particularly in patients treated with peritoneal dialysis (PD). Aluminum-related bone disease is much less common than previously described, perhaps in relation to the declining use of aluminum as a phosphate binder. A different pattern of bone lesions is seen in PD as compared with hemodialysis (HD), with low turnover disorders comprising 66% of the lesions seen in PD and high turnover lesions accounting for 62% of the bone histologic findings in HD. The difference in these patterns may relate to alterations in PTH levels, as mean PTH levels in HD patients were 2-1/2 times the levels found in PD patients (P < 0.0005), while older age, higher prevalence of diabetes and a shorter duration of dialysis may also have contributed to the findings in the PD patients. We suggest that PD, perhaps by maintaining calcium at higher levels, may more effectively suppress the parathyroid gland.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8441240     DOI: 10.1038/ki.1993.64

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  81 in total

Review 1.  Renal osteodystrophy.

Authors:  E A González; K J Martin
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

2.  The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis.

Authors:  Naro Ohashi; Toshihiko Uematsu; Satoru Nagashima; Mitsutaka Kanamaru; Akashi Togawa; Akira Hishida; Eiji Uchida; Tadao Akizawa; Shozo Koshikawa
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

3.  Correction of metabolic acidosis with potassium citrate in renal transplant patients and its effect on bone quality.

Authors:  Astrid Starke; Alf Corsenca; Thomas Kohler; Johannes Knubben; Marius Kraenzlin; Daniel Uebelhart; Rudolf P Wüthrich; Brigitte von Rechenberg; Ralph Müller; Patrice M Ambühl
Journal:  Clin J Am Soc Nephrol       Date:  2012-07-05       Impact factor: 8.237

4.  Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.

Authors:  S Gonnelli; A Montagnani; C Caffarelli; A Cadirni; M S Campagna; M B Franci; B Lucani; E Gaggiotti; R Nuti
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

Review 5.  Renal osteodystrophy for nonnephrologists.

Authors:  William G Goodman
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

Review 6.  Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease.

Authors:  Ziad Massy; Tilman Drueke
Journal:  J Nephrol       Date:  2017-04-12       Impact factor: 3.902

Review 7.  New options for the management of hyperparathyroidism after renal transplantation.

Authors:  Walter Guillermo Douthat; Carlos Raul Chiurchiu; Pablo Ulises Massari
Journal:  World J Transplant       Date:  2012-06-24

8.  Determinants of prevalent vertebral fractures and progressive bone loss in long-term hemodialysis patients.

Authors:  Jan Mares; Kristina Ohlidalova; Sylvie Opatrna; Jiri Ferda
Journal:  J Bone Miner Metab       Date:  2009-01-27       Impact factor: 2.626

Review 9.  The kidney and bone metabolism: Nephrologists' point of view.

Authors:  Masafumi Fukagawa; Yasuhiro Hamada; Shohei Nakanishi; Motoko Tanaka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

10.  CYP2D6, GST-M1 and GST-T1 enzymes: expression in parathyroid gland and association with the parathyroid hormone concentration during early renal replacement therapy.

Authors:  Feng-Xiang Yan; M Chris Langub; Mark A Ihnen; Carlton Hornung; Erkki Juronen; Mary K Rayens; Wei-Min Cai; Peter J Wedlund; Paolo Fanti
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.